Advancements in Prostate Cancer Treatment: Enzalutamide's Impact

Created using ChatSlide

This presentation delves into the pivotal Phase 3 EMBARK trial, emphasizing significant advancements in metastatic-free survival (MFS) through innovative imaging techniques. Attendees will gain insight into the trial's design, its primary and secondary endpoints, and the statistical methods employed. Notable results include 8-year overall survival data and the introduction of novel therapies with no significant safety concerns. The discussion highlights the clinical impact of the findings and...